Boc-2-aminoethanol | 1427379-81-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-2-aminoethanol
• 英文别名: Tert-butyl 3-amino-2-hydroxypropanoate
• CAS: 1427379-81-4
• 化学式: C₇H₁₅NO₃
• mdl: MFCD20717935
• 分子量: 161.201
• InChiKey: IYRULVWLVRRRIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Boc-2-aminoethanol 、 1,1-dimethylethyl α-butyl-γ-carboxy<1,1'-biphenyl>-4-pentanoate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 生成 2-[3-Biphenyl-4-yl-2-(2-tert-butoxycarbonyl-2-hydroxy-ethylcarbamoyl)-propyl]-hexanoic acid tert-butyl ester
  参考文献：
  名称：

  Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors

  摘要：

  The synthesis of three series of dicarboxylic acid dipeptide neutral endopeptidase 24.11 (NEP) inhibitors is described. In particular, the amino butyramide 21a exhibited potent NEP inhibitory activity (IC50 = 5.0 nM) in vitro and in vivo. Blood levels of 21a were determined using an ex vivo method by measuring plasma inhibitory activity in conscious rats, mongrel dogs, and cynomolgus monkeys. Free drug concentrations were 10-1500 times greater than the inhibitory constant for NEP over the course of a 6 h experiment. A good correlation of free drug concentrations was obtained when comparing values determined by the ex vivo analysis to those calculated from direct HPLC measurements. Plasma atrial natriuretic factor (exogenous) levels were elevated in rats and dogs after oral administration of 19a. Urinary volume and urinary sodium excretion were also potentiated in anesthetized dogs treated with 21a.

  DOI：

  10.1021/jm00010a014
• 作为产物：
  描述：

  C.I.酸性橙108 、 二碳酸二叔丁酯 、 potassium hydrogensulfate 在 4-二甲氨基吡啶 Sodium sulfate-III 作用下， 以 乙腈 、 Brine 为溶剂， 反应 3.0h， 以pure Boc-ethanolamine 29 is obtained in 53% yield的产率得到Boc-2-aminoethanol
  参考文献：
  名称：

  1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS

  摘要：

  本发明涉及具有1,2,3-三氮唑环的化合物领域，其化学式为（I），并具有鸟氨酸和羧基或其异构体，通过Cu催化的“点击化学”制备，以及在血管生成异常的病理学中的医疗诊断用途，例如肿瘤起源的病理条件、肿瘤转移、骨质疏松和类风湿性关节炎。

  公开号：

  US20130040964A1

文献信息

• PHARMACEUTICAL COMPOSITION FOR RESPIRATORY ADMINISTRATION
  申请人：SEIKAGAKU CORPORATION

  公开号：US20160158369A1

  公开（公告）日：2016-06-09

  The present invention provides a pharmaceutical composition for respiratory administration containing a polysaccharide derivative having a group derived from a polysaccharide and a group derived from a physiologically active substance that is covalently bonded to the group derived from a polysaccharide.

  本发明提供了一种用于呼吸给药的药物组合物，其含有一个多糖衍生物，该多糖衍生物具有一个源自多糖的基团和一个源自生理活性物质的基团，该生理活性物质基团与源自多糖的基团共价结合。
• [EN] LIBRARIES OF PYRIDINE-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] BIBLIOTHÈQUES DE COMPOSÉS MACROCYCLIQUES CONTENANT DE LA PYRIDINE ET LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：CYCLENIUM PHARMA INC

  公开号：WO2018232506A1

  公开（公告）日：2018-12-27

  The present disclosure relates to novel pyridine-containing macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

  本公开涉及新型含吡啶的大环化合物及其库，这些化合物对药物发现工作是有用的研究工具。本公开还涉及制备这些化合物和库的方法，以及使用这些库的方法，例如在高通量筛选中。特别是，这些库对评估现有和新鉴定的药理学相关靶点的生物活性是有用的，包括G蛋白偶联受体、核受体、酶、离子通道、转运蛋白、转录因子、蛋白质相互作用和核酸-蛋白质相互作用。因此，这些库可应用于寻找用于治疗和预防各种医疗状况的新药物。
• LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：CYCLENIUM PHARMA INC.

  公开号：US20190153620A1

  公开（公告）日：2019-05-23

  The present disclosure relates to novel macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

  本公开涉及新颖的大环化合物及其库，这些化合物可作为药物发现工作的研究工具。本公开还涉及制备这些化合物和库的方法，以及使用这些库的方法，例如在高通量筛选中的应用。特别是，这些库可用于评估现有和新鉴定的药理相关靶点的生物活性，包括G蛋白偶联受体、核受体、酶、离子通道、转运蛋白、转录因子、蛋白质相互作用和核酸-蛋白质相互作用。因此，这些库可应用于寻找用于治疗和预防各种医疗状况的新药物。
• ISOCYANATE MANUFACTURE
  申请人：Bhattacharyya Subha

  公开号：US20120202961A1

  公开（公告）日：2012-08-09

  The present invention encompasses the finding that improvements can be achieved in manufacture of isocyanates through the use of a substitute for or a precursor of phosgene. Methods and compositions utilized in accordance with the present invention can be useful in situations in which it is difficult to use phosgene, and in particular gaseous phosgene. In some embodiments, a substitute for or a precursor of phosgene used in accordance with the present invention for preparing isocyanates is or comprises diphosgene (ClCO 2 CCl 3 ).

  本发明涵盖了一项发现，即可以通过使用对光气的替代物或前体来改进异氰酸酯的制造。根据本发明使用的方法和组合物可以在难以使用光气，特别是气态光气的情况下发挥作用。在某些实施例中，根据本发明用于制备异氰酸酯的对光气的替代物或前体是或包括二光气（ClCO2CCl3）。
• [EN] LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] BIBLIOTHÈQUES DE COMPOSÉS MACROCYCLIQUES CONTENANT HÉTÉROARYLE ET PROCÉDÉS POUR LEUR FABRICATION ET LEUR UTILISATION
  申请人：CYCLENIUM PHARMA INC

  公开号：WO2017049383A1

  公开（公告）日：2017-03-30

  The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

  本公开涉及新型大环化合物及其库，其中包含对药物发现工作有用的含杂环芳基团的化合物。本公开还涉及制备这些化合物和库的方法，以及使用这些库的方法，例如在高通量筛选中使用。特别是，这些库可用于评估现有和新鉴定的药理学相关靶点的生物活性，包括G蛋白偶联受体、核受体、酶、离子通道、转运蛋白、转录因子、蛋白质相互作用和核酸-蛋白质相互作用。因此，这些库可应用于寻找用于治疗和预防各种医疗状况的新药物。